Comparative study of outcomes following laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in morbidly obese patients: A case control study

Table 1 Baseline characteristics of study population (n = 80)

Parameter	LRYGB group (n = 40)	LSG group (n = 40)	P value
Age (yr)	44.6 ± 10.2	44.8 ± 10.2	NS
Gender
Female, n (%)	29 (72.5%)	29 (72.5%)	NS
Male, n (%)	11 (27.5%)	11 (27.5%)	NS
Weight (kg)	109.9 ± 13.9	113.6 ± 15.2	NS
Body mass index (kg/m2)	43.9 ± 5.5	45.8 ± 4.8	NS
Excess weight (kg)	46.9 ± 12.7	51.3 ± 12.2	NS
Comorbidities
Type 2 diabetes mellitus, n (%)	27 (67.5%)	27 (67.5%)	NS
Patients on insulin	5 (18.5%)	5 (18.5%)	NS
aNumber of OHA	2.2 ± 0.7	1.8 ± 0.7
abDuration (yr)	7 (5-7)	5 (3-7)
Hypertension, n (%)	25 (62.5%)	23 (57.5%)	NS
Number of AHA	1.7 ± 0.7	1.7 ± 0.8	NS
OSAS, n (%)	7 (17.5%)	2 (5%)	NS
Hypothyroidism, n (%)	11 (27.5%)	7 (17.5%)	NS
Thyroxine dosage (µg/d)	90.9 ± 25.7	89.9 ± 31.8	NS
GERD, n (%)	7 (17.5%)	4 (10%)	NS

All P values are non-significant except

^aP value < 0.05 as assessed by Student’s t test; All data expressed as mean ± SD except

^bwhere data is presented as median (Interquartile range). AHA: Anti-hypertensive agents; GERD: Gastroesophageal reflux disease; OHA: Oral hypoglycemic agents; OSAS: Obstructive sleep apnea syndrome; LRYGB: Laparoscopic Roux-en-Y gastric bypass; LSG: Laparoscopic sleeve gastrectomy.

Table 2 Impact of bariatric surgery on comorbidities (n = 80)

Comorbidity	LRYGB			LSG			P value1
	Preoperative	Resolution	Improvement	Preoperative	Resolution	Improvement
Type 2 diabetes mellitus	27	18	9	27	21	6	0.36
Hypertension	25	11	12	23	8	14	0.64
OSAS	7	7	0	2	2	0	-
Hypothyroidism	11	3	6	7	1	3	0.58

¹All P values were calculated by applying χ² test for every comorbidity comparing LSG and LRYGB. OSAS: Obstructive sleep apnea syndrome; LRYGB: Laparoscopic Roux-en-Y gastric bypass; LSG: Laparoscopic sleeve gastrectomy.

Table 3 Impact of bariatric surgery on medications for various comorbidities (n = 80)

Medications	LRYGB		LSG		P value1
	Preoperative period	Postoperative period	Preoperative	Postoperative period
Number of OHA	2.17 ± 0.7	0.3 ± 0.5	1.8 ± 0.7	0.3 ± 0.6	0.73
Number of AHA	1.7 ± 0.7	0.5 ± 0.5	1.7 ± 0.8	0.6 ± 0.6	0.78
Dosage of thyroxine (μg/d)	90.9 ± 25.7	45.5 ± 40.1	89.3 ± 31.8	53.6 ± 39.3	0.33

All data expressed as mean ± SD.

¹All P values were calculated using Student’s t test separately for all comorbidities. AHA: Anti-hypertensive agents; OHA: Oral hypoglycemic agents; LRYGB: Laparoscopic Roux-en-Y gastric bypass; LSG: Laparoscopic sleeve gastrectomy.